Navigation Links
Testosterone Lawsuit News: New Order Outlines Discovery Plan for Federal Testosterone Treatment Litigation, Bernstein Liebhard LLP Reports

New York, New York (PRWEB) September 03, 2014

Testosterone lawsuits ( filed on behalf of men who allegedly suffered serious cardiovascular problems due to their use of AndroGel and other low testosterone therapy medications continue to move forward in U.S. District Court, Northern District of Illinois, Bernstein Liebhard LLP reports. According to a Case Management Order issued on August 25, 2014, the Court has established a discovery plan for the proceeding. Among other things, the Order directs the parties to submit initial disclosures regarding certain potential witnesses and documents within the next 45 days. The parties must also continue negotiations regarding the contents of a Plaintiff’s Fact Sheet in advance of the litigation’s September Status Conference. (In re: Testosterone Replacement Therapy Product Liability Litigation - MDL No. 2545)

“Our Firm has heard from a number of men who were allegedly injured by AndroGel and other prescription treatments for low testosterone. We are pleased to see this litigation moving forward,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is now evaluating testosterone lawsuits on behalf of men who allegedly suffered heart attacks, strokes, deep vein thrombosis, pulmonary embolism and other life-threatening heart problems due to their use of prescription testosterone medications.

Testosterone Treatment Lawsuits

Court documents indicate that just over 170 testosterone treatment lawsuits are now pending in the Northern District of Illinois. All of the claims filed thus far accuse the manufacturers of AndroGel, AndroDerm, Testim and other testosterone replacement therapies of concealing the cardiovascular risks associated with their products, and of failing to warn doctors and patients about their potential to cause serious heart problems.

According to court records, testosterone lawsuit filings began to grow shortly after the U.S. Food & Drug Administration (FDA) announced that it was investigating the cardiovascular risks potentially associated with this class of drugs. The agency is scheduled to convene an outside panel of advisors on September 17th to discuss this matter, and to explore ways in which such risks might be mitigated.

Men who allegedly experienced dangerous cardiovascular events due to low testosterone therapy may be entitled to compensation for their injury-related damages. Find out more about filing a testosterone treatment lawsuit by visiting Bernstein Liebhard LLP’s website, or calling the Firm today at 800-511-5092.

*, FDA, July 17, 2014

About Bernstein Liebhard LLP

Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs' Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.

Bernstein Liebhard LLP

10 East 40th Street

New York, New York 10016


ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:

Felecia L. Stern, Esq.

Bernstein Liebhard LLP

info (at) consumerinjurylawyers (dot) com

Read the full story at

Source: PRWeb
Copyright©2014 Vocus, Inc.
All rights reserved

Related medicine news :

1. Methadone treatment suppresses testosterone in opioid addicts
2. Testosterone Therapy Lawsuits: AndroGel Manufacturer Files Petition Against FDA's Decision on Generic Testosterone Treatment Drug
3. Testosterone Treatment Lawsuit News: Federal Court OverseeingTestosterone Litigation Convenes Conference to Discuss Pretrial Management, Bernstein Liebhard LLP Reports
4. Testosterone Lawsuits Involving AndroGel, other Prescription Therapies Move Forward in Illinois Federal Court Litigation, Bernstein Liebhard LLP Reports
5. Testosterone Treatment Lawsuit News: New Filing Alleges Depo-Testosterone Caused Life-Threatening Heart Problems, Bernstein Liebhard LLP reports.
6. Common Chemicals May Lower Testosterone Levels, Study Finds
7. Testosterone Lawsuit Alleges AndroDerm Patch Caused Death of Virginia Man, Bernstein Liebhard LLP Reports
8. Partner Kristine Kraft Appointed to the Plaintiffs’ Steering Committee (PSC) in Federal Testosterone Replacement Therapy MDL, Schlichter, Bogard & Denton, LLP Reports
9. Testosterone in healthy men increases their brains response to threat
10. FDA Seeks Answers As Testosterone Lawsuits Mount Against "Low T" Drug Makers
11. Testosterone Lawsuit News: Bernstein Liebhard LLP Notes Report Indicating That More Men are Seeking Prescription Supplements
Post Your Comments:
(Date:11/24/2015)... ... ... Charitable giving is at its peak during the holidays. In fact, ... the year totalling over $358 billion in 2014. With more than 1.5 million ... individuals who want to “give back” during the holidays. , “With so many charities ...
(Date:11/24/2015)... ... November 24, 2015 , ... In an article ... variables that determine which patients are or are not eligible for bariatric surgery. The ... BMI over 40, are more than 100 pounds overweight, or have a BMI of ...
(Date:11/24/2015)... ... ... DMG Productions announced that they will feature Aphria, Inc., in an upcoming episode ... and show times TBA. , Aphria, Inc., is a publicly traded company incorporated under ... medical marijuana pursuant to the Marijuana for Medical Purposes Regulations (the “MMPR”). , Aphria ...
(Date:11/24/2015)... ... ... Preparing for the LDT Regulation:, CLIA Won’t Satisfy the FDA, Dec. ... has long asserted that design and manufacture of Laboratory Developed Tests (LDTs) falls under ... the device regulations. , Come up short in an inspection and the FDA can ...
(Date:11/24/2015)... ... November 24, 2015 , ... ... organization will waive paid entry and parking fees at several of their most ... Mountain in Great Barrington in support of REI’s Black Friday #OptOutside Campaign. The ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... -- Today AVACEN Medical announced the issue of United States patent No. 9,192,509 ... This patent shields the company,s AVACEN 100 dry heat therapy medical device and specific methods of ... Photo - ... ... ...
(Date:11/25/2015)... -- Endo International plc (NASDAQ: ENDP ) (TSX: ENL) ... CEO, will discuss corporate updates at the 27 th ... on Wednesday, December 2, 2015 at 1 p.m. ... and then the link to the event. Participants should allow ... visit the site and download any streaming media software needed ...
(Date:11/25/2015)... November 25, 2015 --> ... blood glucose devices was valued at $11,171.1 million in ... CAGR of 5.7% during 2015 - 2022. The global ... increasing prevalence of diabetes. In addition, the increase in ... also contributing to the growth of the market. Furthermore, ...
Breaking Medicine Technology: